Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to “Hold” at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein decreased their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $255.13 on Wednesday. The firm’s 50-day moving average price is $247.93 and its two-hundred day moving average price is $255.50. Alnylam Pharmaceuticals has a 12-month low of $144.73 and a 12-month high of $304.39. The stock has a market capitalization of $33.19 billion, a price-to-earnings ratio of -117.57 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. During the same quarter last year, the firm earned ($0.16) EPS. The company’s revenue for the quarter was up 20.2% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,392 shares of company stock worth $1,875,627. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Allworth Financial LP increased its holdings in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the last quarter. Investment Management Corp of Ontario increased its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after purchasing an additional 40 shares during the last quarter. Nixon Peabody Trust Co. increased its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 43 shares during the last quarter. Brevan Howard Capital Management LP increased its holdings in shares of Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 44 shares during the last quarter. Finally, IFP Advisors Inc increased its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.